Hepatology

Top Story

Statin use associated with dose-dependent reduction in cirrhosis and HCC in patients with HCV

Statin use associated with dose-dependent reduction in cirrhosis and HCC in patients with HCV
July 27, 2016

In patients with hepatitis C, both atorvastatin and fluvastatin use were associated with a dose-dependent reduction in both cirrhosis and hepatocellular carcinoma, according to recent findings published in Hepatology.

“This was the first study of patients with chronic HCV to be associated with a clear, dose-dependent reduction in rates of both incident cirrhosis and HCC with statins, independent of fibrosis stage or attainment of sustained viral response,” Raymond T. Chung, PhD, director of Hepatology and Liver Center at Massachusetts General Hospital, told Healio.com/Hepatology. “We also observed a difference in effect according to statin type, with the greatest antifibrotic benefits seen in users of atorvastatin and fluvastatin, a finding we hope to validate in future studies.”

Women of childbearing age show increased risk for HCV

July 27, 2016
Women of childbearing age in Kentucky and nationally had increased rates of hepatitis C virus detection between 2011 and 2014, according to new data published in…
In the Journals

Researchers develop liver model displaying metabolism zonation

July 27, 2016
According to data published in Scientific Reports, researchers at Massachusetts General Hospital developed a liver model displaying zonation of distinct metabolisms…
Meeting News Coverage

Novel HCV DAAs could be mass-produced under $90 per person

July 26, 2016
If international donors place larger orders, novel direct-acting antivirals to treat hepatitis C could be mass-produced for under $90 per person, according to an…
FDA approvals

FDA approves Viekira XR for HCV genotype 1

July 26, 2016
The FDA has approved a new drug application for Viekira XR — an extended-release, coformulation of the active ingredients in Viekira Pak — for the treatment…
More News Headlines »
CME

Rapid Response from Barcelona: New Data in HCV Treatment

This activity is supported by an educational grant from AbbVie and Merck & Co., Inc.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
GI Bookshelf

Question 46: My Patient With Hepatic Encephalopathy Continues To Be Mildly Confused Despite Taking Lactulose Twice Daily And Having Multiple Episodes Of Diarrhea Daily. Should I Increase The Dose Further?

From Curbside Consultation of the Liver: 49 Clinical Questions
More »
Featured
Highlights from International Liver Congress

Highlights from International Liver Congress

Video
Meeting News Coverage

VIDEO: Chronic liver disease has significant patient impact, economic burden

May 22, 2016
More »
Current Issues Current Issues
View the Current Issue
HCV Next
morganatic-roan